Medicure presents phase 2 Matched study results

By Elaine Rigoli

Tampa, Fla., May 17 - Medicure Inc. announced data from two poster presentations on the phase 2 Matched study at the 21st annual meeting of the American Society of Hypertension.

Data presented from the poster titled "The Combination of MC-1 and Lisinopril Has Beneficial Effects on Carbohydrate and Lipid Metabolism in Hypertensives with type 2 Diabetes Mellitus" included previously released metabolic results as well as new lipid results from Matched:

• The 300 mg/20 mg (MC-1/lisinopril) dose of MC-4232 had a reduction in fasting serum glucose of 1.45 mmol/L versus a placebo;

• In patients with elevated baseline triglycerides, the 300 mg/20 mg dose of MC-4232 had a reduction of 0.7 mmol/L versus baseline;

• In patients with elevated baseline LDL (greater than or equal to 2.6 mmol/L), the 300 mg/20 mg dose of MC-4232 had a reduction of 0.4 mmol/L versus baseline.

Data presented from the poster titled "Evaluation of the Antihypertensive Effects of MC-1 Alone and in Combination with Lisinopril on Ambulatory BP in Hypertensive Patients with type 2 Diabetes Mellitus" showed:

• The 300 mg/20 mg dose of MC-4232 had a reduction in mean daytime ambulatory systolic blood pressure of 12.0 mmHg from baseline after eight weeks of therapy as compared to 7.5 mmHg with 20 mg lisinopril monotherapy, equating to an additional 4.5 mmHg reduction;

• The 300 mg/20 mg dose of MC-4232 had a reduction in mean daytime ambulatory diastolic blood pressure of 7.5 mmHg from baseline after eight weeks of therapy as compared to a 4.1 mmHg reduction with 20 mg lisinopril monotherapy, equating to an additional 3.4 mmHg reduction.

Medicure completed the phase 2 study in September 2005.

Matched was a randomized, parallel group, cross-over, double-blind, placebo-controlled comparison of 100, 300 or 1,000 mg of MC-1 alone and in combination with 20 mg of lisinopril. The study results are based on a population of 120 patients with coexisting type 2 diabetes and hypertension from 12 sites across Canada.

Medicure is a cardiovascular drug discovery and development company focused on developing therapeutics for unmet needs in the field of cardiovascular medicine, located in Winnipeg, Man.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.